Parkinson's disease
IV mesenchymal stem cell protocols for mild-to-moderate Parkinson's disease — adjunctive to neurology care, never a replacement for it. Recent phase 2 data is the most promising signal in regenerative neurology.
- Class
- Neurodegenerative
- Approach
- IV systemic, multi-dose
- Materials
- MSC · exosome
- Coordination
- With movement-disorders neurologist
01 About
What Parkinson's is.
Parkinson's disease is a neurodegenerative disorder driven by the progressive loss of dopaminergic neurons in the substantia nigra. The classic motor symptoms — tremor, bradykinesia, rigidity, postural instability — emerge once a substantial fraction of those neurons have already been lost. Standard treatment is dopamine replacement (carbidopa-levodopa), dopamine agonists, MAO-B inhibitors, and (for select patients) deep brain stimulation.
Stem cell therapy is being studied as a disease-modifying addition — not a symptom replacement. The goal is to slow progression and support the neurons that remain, while patients continue their movement-disorders specialist's recommended regimen.
02 How it works
How regen supports the dopaminergic system.
Mesenchymal stem cells delivered intravenously exert paracrine effects on the central nervous system: they modulate neuroinflammation, release neurotrophic factors (GDNF, BDNF) that support remaining dopaminergic neurons, and may reduce alpha-synuclein-driven cellular stress. Animal models consistently show preservation of dopamine cell populations and behavioral improvement after MSC administration.
The dosing question matters. Recent trials suggest that repeated infusions over months produce stronger signals than single doses — consistent with the idea that MSC effects are paracrine and require sustained presence to drive durable change.
03 What the research shows
What the studies show.
Parkinson's evidence has improved meaningfully in 2024–2025 with the publication of phase 2 data showing significant motor improvement. The dose and frequency of MSC administration appears to matter substantially.
Allogeneic Bone Marrow-Derived MSCs for Parkinson's Disease
A phase 2, randomized, placebo-controlled trial of allogeneic human MSCs in 45 patients with mild-to-moderate Parkinson's. Three infusions of 10 million MSCs/kg significantly improved motor function (UPDRS Part III) compared with placebo. Two infusions showed less improvement than placebo — a striking dose-response signal.
Read on PubMedAdipose-Derived MSCs (HB-adMSC) for Early-to-Moderate Parkinson's
A phase 2 trial of adipose-derived MSC therapy in early-to-moderate Parkinson's met its primary endpoint, with patients receiving cell therapy showing a placebo-adjusted -9.32-point reduction in MDS-UPDRS Part III by the sixth infusion — clinically meaningful motor improvement that has prompted FDA discussion of phase 3.
Read on NeurologyLiveMSC Therapy in Parkinson's Disease: A Comprehensive Review
A 2024 comprehensive review of MSC therapy for Parkinson's. The review summarizes mechanism, accumulating clinical evidence, and current research priorities — highlighting the recent shift from "promising but unproven" to "first phase 2 efficacy signals" in the literature.
Read on Cureus
Parkinson's is currently the strongest neurodegenerative-disease signal in the regenerative literature. We are still measured: this is adjunctive therapy, not a cure, and dose schedule matters.
04 Are you a candidate
Who's a candidate.
Candidates:
- Mild to moderate idiopathic Parkinson's disease (Hoehn & Yahr stage 1–3).
- Patients on appropriate medical management with their movement-disorders neurologist.
- Patients seeking disease-modifying adjunct therapy, with realistic expectations about modest functional benefit.
- Stable medical status with no contraindications to IV therapy.
When we will not recommend it:
- Atypical parkinsonian syndromes (PSP, MSA, CBD) — different mechanism, different evidence.
- Patients seeking to discontinue medication management.
- End-stage disease where realistic expectations cannot be set.
- Patients without confirmed PD diagnosis from a neurologist.
Think you might be a candidate?
The first step is a 60–90 minute consultation. We review your imaging, history, and goals — and tell you honestly whether regenerative therapy is the right next step.
05 A patient experience
Dr. Abdullah did an amazing job treating both me and my spouse. I feel less pain every day, and my brain fog is entirely gone. It's only been about 3 weeks.
Kayla Google · Local Guide
07What happens at your consultation
A conversation, not a sales meeting.
-
01
Intake & history
60–90 minutes. We review imaging, prior treatments, current medications, and goals. Most of this hour is listening.
-
02
Focused exam
A clinical exam tailored to your indication. Range of motion, strength, functional testing — what the literature actually predicts response on.
-
03
Honest candidacy review
If we think you're a candidate, we'll tell you why. If we don't, we'll tell you what we'd recommend instead — surgery, PT, watchful waiting.
-
04
Written plan & pricing
A defined treatment plan with modality, sequence, follow-up cadence, and total cost — before any commitment.
06 What treatment looks like
What treatment looks like.
A typical Parkinson's protocol begins with consultation, neurology coordination, and review of medication regimen, MRI (when relevant), and disease history. Treatment is a series of IV systemic MSC infusions — typically multiple doses spaced weeks to months apart — based on the phase 2 evidence that repeated dosing matters.
Reassessment at 3, 6, and 12 months. UPDRS scoring, symptom tracking, and ongoing coordination with the movement-disorders neurologist.
09 Common questions
Common questions, answered.
Will this stop my Parkinson's progression?
Recent phase 2 trials show meaningful motor improvement. We're honest about what the data does and does not support — this is adjunctive, not a cure.
Should I continue my Parkinson's medications?
Yes — always. Regenerative therapy is adjunctive to neurology care, never a replacement.
Is one infusion enough?
Recent trial data suggests three infusions outperform one. Single doses showed less consistent benefit. The dose schedule matters.
Will this help non-motor symptoms?
Some patients report cognitive and mood improvement. Motor outcomes (UPDRS Part III) are the most studied endpoint.
How is this different from DBS?
DBS modulates neural signaling. Regenerative therapy aims to support the dopaminergic system itself — different mechanism, different patient profile.
What are the risks?
IV MSC protocols are well-tolerated in published Parkinson's trials. Brief post-infusion fatigue is the most common effect.
08 Coverage & cost
Most regenerative protocols at Apex are not covered by insurance — we discuss pricing directly, in writing, before any commitment. Softwave shockwave is the exception: covered by Medicare Parts A & B with supplement (not by Medicare Advantage). Financing options are available for protocols not covered. We never hold a pricing conversation until we know you're a candidate.
Begin with a consultation.
A frank conversation about your Parkinson's, your current treatment, and whether regenerative therapy is the right adjunct — including a clear discussion of the recent phase 2 evidence and what it does and does not show.